Prof. Dr. Andreas E. Kulozik
Director Pediatric Oncology, Hematology and Immunology, Heidelberg

Department of Pediatric Oncology, Hematology and Immunology
Im Neuenheimer Feld 153
69120 Heidelberg

06221 56 4555 (phone)
06221 56 4559 (fax)
andreas.kulozik@med.uni-heidelberg.de

9.4.1959

SCIENTIFIC VITA

1978-1984	Medical School; Universities of Münster/Westf. and Glasgow, UK
1980-1984	Studienstiftung des Deutschen Volkes
1984/1985	Graduation and MD degree Institute of Human Genetics University of Münster
1985-1987	DFG training stipend
1985-1987	Research Fellow; MRC Molecular Haematology Unit, Nuffield Department of Medicine, University of Oxford, UK
1987	PhD degree Medical Research Council Molecular Haematology Unit, Nuffield Department of Medicine, University of Oxford, UK
1987-1993	Clinical training and research fellow; Department of Pediatrics; University of Ulm
1993	Board Certification in Pediatrics
1993	Habilitation Pediatrics, University of Ulm
1993-1994	Senior physician and Lecturer; Children's Hospital; University of Ulm
1994-1996	Senior physician and Senior Lecturer; Children's Hospital; Charité, Humboldt University Berlin
1996-2001	Associate professor and associate director, Department of Pediatrics; Charité, Humboldt University, Berlin
since 2001	Full Professor and Medical Director; Department of Pediatric Oncology, Hematology and Immunology; University of Heidelberg

AWARDS

British Society for Haematology Young Investigators Prize (1987); 1993; Adalbert-Czerny-Prize of the German Society of Pediatrics (1993); 1994; University of Ulm Merckle-Research Prize (1994); 2005; Elected Member of the European Molecular Biology Organisation (EMBO, 2005)

FIELDS OF INTEREST

Post-transcriptional regulation of gene expression, RNA stability, Leukemia in childhood, Thrombophilia, Hemoglobin disorders

SELECTED PUBLICATIONS (SINCE 2000)

Breit S, Stanulla M, Flohr T, Schrappe M, Ludwig WD, Tolle G, Happich M, Muckenthaler MU, Kulozik AE (2006). Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. **Blood** 108, 1151-1157

Gehring N, Kunz JB, Neu-Yilik G, Breit S, Viegas MH, Hentze MW, Kulozik AE (2005). Exon-junction components specify distinct routes of nonsense-mediated mRNA decay with differential co-factor requirements. **Mol Cell** 20: 65-75 (2005).

Holbrook J, Neu-Yilik G, Hentze MW, Kulozik AE (2004). Nonsense mediated decay approaches the clinic. **Nat Genet** 36, 801-809

Danckwardt S, Gehring NH, Neu-Yilik G, Hundsdoerfer P, Pforsich M, Hentze MW, Kulozik AE (2004). The prothrombin 3'end formation signal reveals a unique architecture that is sensitive to thrombophilic gain-of-function mutations. **Blood** 104, 428-435

Gehring NH, Neu-Yilik G, Schell T, Hentze MW, Kulozik AE (2003). Y14 and hUpf3b form an NMD-activating complex. **Mol Cell** 11, 939-949

Danckwardt S, Neu-Yilik G, Thermann R, Frede U, Hentze MW, Kulozik AE (2002). Abnormally spliced β-globin mRNAs: A single point mutation generates NMD-sensitive and NMD-insensitive transcripts. **Blood** 99, 1811-1816

Gehring NH, Frede U, Neu-Yilik G, Hundsdoerfer P, Hentze MW, Kulozik AE (2001). Increased efficiency of mRNA 3' end formation: a novel genetic mechanism contributing to hereditary thrombophilia. **Nat Genet** 28, 389-392

Neu-Yilik G, Gehring NH, Thermann R, Frede U, Hentze MW, Kulozik AE (2001). Splicing and 3' end formation in the definition of NMD competent human β-globin mRNPs. **EMBO J** 20, 532-540

Kebelmann-Betzing C, Seeger K, Kulozik A, Henze G, Liehr T, Heller A, Teigler-Schlegel A (2000). Secondary acute myeloid leukemia after treatment of acute monoblastic leukemia. **N Engl J Med** 343, 1897-1898

Reich S, Buhrer C, Henze G, Ohlendorf D, Mesche M, Sinha P, Kage A, Muller C, Vetter B, Kulozik AE (2000). Oral isobutyramide reduces transfusion requirements in some patients with homozygous beta-thalassemia. **Blood** 96, 3357-3363.